Therefore, they successfully tested a third-generation dual CAR-T-APRIL (a ligand for BCMA and TACI), which eliminated MM cells expressing either BCMA or TACI and demonstrated tumor control in the absence of BCMA [43]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.